Kim Bumki, Ratnayake Ranjala, Lee Hyunji, Shi Guqin, Zeller Sabrina L, Li Chenglong, Luesch Hendrik, Hong Jiyong
Department of Chemistry, Duke University, Durham, NC 27708, United States.
Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, United States; Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, FL 32610, United States.
Bioorg Med Chem. 2017 Jun 15;25(12):3077-3086. doi: 10.1016/j.bmc.2017.03.071. Epub 2017 Apr 4.
Histone acetylation is an extensively investigated post-translational modification that plays an important role as an epigenetic regulator. It is controlled by histone acetyl transferases (HATs) and histone deacetylases (HDACs). The overexpression of HDACs and consequent hypoacetylation of histones have been observed in a variety of different diseases, leading to a recent focus of HDACs as attractive drug targets. The natural product largazole is one of the most potent natural HDAC inhibitors discovered so far and a number of largazole analogs have been prepared to define structural requirements for its HDAC inhibitory activity. However, previous structure-activity relationship studies have heavily investigated the macrocycle region of largazole, while there have been only limited efforts to probe the effect of various zinc-binding groups (ZBGs) on HDAC inhibition. Herein, we prepared a series of largazole analogs with various ZBGs and evaluated their HDAC inhibition and cytotoxicity. While none of the analogs tested were as potent or selective as largazole, the Zn-binding affinity of each ZBG correlated with HDAC inhibition and cytotoxicity. We expect that our findings will aid in building a deeper understanding of the role of ZBGs in HDAC inhibition as well as provide an important basis for the future development of new largazole analogs with non-thiol ZBGs as novel therapeutics for cancer.
组蛋白乙酰化是一种经过广泛研究的翻译后修饰,作为一种表观遗传调节因子发挥着重要作用。它由组蛋白乙酰转移酶(HATs)和组蛋白去乙酰化酶(HDACs)控制。在多种不同疾病中都观察到HDACs的过表达以及随之而来的组蛋白低乙酰化,这使得HDACs最近成为有吸引力的药物靶点。天然产物拉加唑是迄今为止发现的最有效的天然HDAC抑制剂之一,并且已经制备了许多拉加唑类似物来确定其HDAC抑制活性的结构要求。然而,先前的构效关系研究主要集中在拉加唑的大环区域,而对于各种锌结合基团(ZBGs)对HDAC抑制作用的研究却很少。在此,我们制备了一系列带有不同ZBGs的拉加唑类似物,并评估了它们的HDAC抑制活性和细胞毒性。虽然所测试的类似物均不如拉加唑有效或具有选择性,但每个ZBG的锌结合亲和力与HDAC抑制活性和细胞毒性相关。我们期望我们的研究结果将有助于更深入地理解ZBGs在HDAC抑制中的作用,并为未来开发以非硫醇ZBGs作为癌症新型治疗药物的新型拉加唑类似物提供重要依据。